Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TRVI | Trevi Therapeutics, Inc.

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	3.69%	Shs Outstand	98.70M	Perf Week	0.94%
Market Cap	123.31M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-0.19%	Shs Float	61.63M	Perf Month	-4.04%
Income	-27.30M	PEG	-	EPS next Q	-0.09	Inst Own	82.20%	Short Float / Ratio	2.13% / 7.20	Perf Quarter	-22.46%
Sales	-	P/S	-	EPS this Y	69.60%	Inst Trans	56.62%	Short Interest	1.31M	Perf Half Y	18.89%
Book/sh	0.96	P/B	2.23	EPS next Y	-28.10%	ROA	-23.30%	Target Price	7.33	Perf Year	-12.65%
Cash/sh	1.63	P/C	1.31	EPS next 5Y	-	ROE	-26.40%	52W Range	1.43 - 3.50	Perf YTD	10.88%
Dividend	-	P/FCF	-	EPS past 5Y	11.10%	ROI	-	52W High	-38.86%	Beta	0.76
Dividend %	-	Quick Ratio	21.10	Sales past 5Y	-	Gross Margin	-	52W Low	49.65%	ATR	0.13
Employees	25	Current Ratio	21.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.75	Volatility	7.14% 5.91%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	64.30%	Profit Margin	-	Rel Volume	0.17	Prev Close	2.16
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	182.60K	Price	2.14
Recom	1.50	SMA20	-3.47%	SMA50	-5.43%	SMA200	-8.00%	Volume	31,020	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-23	Initiated	B. Riley Securities	Buy	$6
Nov-22-22	Initiated	SVB Leerink	Outperform	$6
Jun-03-19	Initiated	SVB Leerink	Outperform	$14
Jun-03-19	Initiated	Stifel	Buy	$20
Jun-03-19	Initiated	Needham	Buy	$18
Jun-03-19	Initiated	BMO Capital Markets	Outperform	$15

Sep-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming September Events (PR Newswire)
Aug-12-23 08:30AM	Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-11-23 06:44AM	Q2 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-03-23 04:05PM	Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 (PR Newswire)
07:30AM	Loading…
Aug-01-23 07:30AM	Trevi Therapeutics to Participate in Upcoming August Events (PR Newswire)
Jul-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming July Investor Events (PR Newswire)
Jun-04-23 10:45AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) top owners are private equity firms with 35% stake, while 32% is held by hedge funds (Simply Wall St.)
May-30-23 07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire) -14.81%
May-22-23 04:05PM	Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence (PR Newswire) -5.00%
May-16-23 11:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 06:38AM	Q1 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.67%
May-11-23 04:05PM	Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-10-23 08:48AM	Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season? (Zacks)
May-09-23 07:30AM	Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 (PR Newswire)
04:05PM	Loading…
May-04-23 04:05PM	Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 (PR Newswire)
May-02-23 07:30AM	Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference (PR Newswire)
Apr-27-23 07:30AM	Trevi Therapeutics to Participate in Upcoming May Investor Events (PR Newswire)
Apr-11-23 04:05PM	Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-18-23 02:03AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:19AM	Q4 2022 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-09-23 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 (PR Newswire) -9.22%
Mar-08-23 07:30AM	Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Mar-06-23 04:05PM	Trevi Therapeutics to Participate in Upcoming March Conferences (PR Newswire)
Feb-21-23 07:00AM	Presenting on the Emerging Growth Conference on February 22 Register Now (GlobeNewswire) -10.73%
Feb-16-23 07:30AM	Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 (PR Newswire)
Feb-02-23 07:30AM	Trevi Therapeutics to Present and Participate in Upcoming February Conferences (PR Newswire) +20.17%
Jan-25-23 09:00AM	Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast (Newsfile)
Jan-05-23 04:05PM	Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences (PR Newswire) +8.49%
08:26AM	Loading…
Dec-26-22 08:26AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) stock price dropped 13% last week; private equity firms would not be happy (Simply Wall St.)
Dec-19-22 04:05PM	Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference (PR Newswire)
Nov-14-22 04:05PM	Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer (PR Newswire)
Nov-10-22 04:05PM	Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Nov-08-22 07:30AM	Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference (PR Newswire)
Nov-03-22 04:05PM	Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 (PR Newswire)
Oct-27-22 07:30AM	Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting (PR Newswire)
Sep-30-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-23-22 01:18AM	/C O R R E C T I O N -- Trevi Therapeutics, Inc./ (PR Newswire) -9.56%
Sep-22-22 04:01PM	Trevi Therapeutics Announces Proposed Public Offering (PR Newswire) -12.24%
Sep-19-22 09:35AM	Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial (Benzinga) -6.13%
07:30AM	Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Sep-14-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-07-22 07:30AM	Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-30-22 04:05PM	Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 (PR Newswire) -9.50%
Aug-24-22 07:30AM	Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release (PR Newswire)
Aug-22-22 09:30AM	Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast (Newsfile)
Aug-11-22 04:05PM	Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update (PR Newswire)
Aug-09-22 07:30AM	Trevi Therapeutics to Present at Upcoming August Conferences (PR Newswire)
Aug-04-22 05:41PM	Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022 (PR Newswire) +5.22%
Jul-21-22 06:45AM	5 Penny Stocks to Buy on the Dip (InvestorPlace) -7.71%
Jul-19-22 09:13AM	Is Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.) +14.33%
Jul-14-22 09:00AM	Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics (ACCESSWIRE) -5.03%
Jul-07-22 07:30AM	Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS) (PR Newswire)
Jun-30-22 12:53PM	Why Did Needham Lift Price Target For Trevi? (Benzinga) +14.69%
Jun-29-22 08:37AM	Why Trevi Therapeutics Shares Trading Higher Today? (Benzinga) +21.29%
08:36AM	Trevi's stock gains 38% after announcing positive data for skin-disease drug (MarketWatch)
07:30AM	Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio in the Treatment of Prurigo Nodularis (PR Newswire)
Jun-23-22 10:58AM	These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer (TipRanks) +17.01%
Jun-07-22 07:30AM	Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention (PR Newswire)
May-12-22 04:05PM	Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update (PR Newswire)
May-05-22 04:05PM	Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022 (PR Newswire) -5.66%
May-03-22 07:30AM	Trevi Therapeutics to Present at Upcoming May Meetings (PR Newswire)
Apr-13-22 04:25PM	Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice (Zacks)
Apr-11-22 08:00AM	Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
Apr-07-22 08:00AM	Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market (PR Newswire) +56.84%
Apr-05-22 04:25PM	Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference (PR Newswire) -8.63%
Mar-23-22 03:25PM	Health Check: How Prudently Does Trevi Therapeutics (NASDAQ:TRVI) Use Debt? (Simply Wall St.)
Mar-22-22 07:30AM	Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire) +14.36%
Mar-17-22 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update (PR Newswire)
Mar-15-22 07:30AM	Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough (PR Newswire) +10.61%
Mar-09-22 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022 (PR Newswire) +8.18%
Feb-24-22 07:55AM	Why Are Trevi Therapeutics Shares Surging During Premarket Thursday? (Benzinga) +6.52%
07:30AM	Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Feb-01-22 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN (PR Newswire) +9.75%
Jan-25-22 10:00AM	Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher (Zacks)
Jan-05-22 07:00AM	Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications (PR Newswire)
Dec-16-21 04:05PM	Trevi Therapeutics to Attend Multiple Conferences in January 2022 (PR Newswire)
Dec-01-21 08:22AM	5 Stocks With Rising P/E Are Good Buys (Zacks)
Nov-18-21 10:21AM	Here's Why Trevi Therapeutics, Inc. (TRVI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-15-21 07:30AM	Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (PR Newswire)
Nov-10-21 04:05PM	Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update (PR Newswire)
Nov-09-21 07:30AM	Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference (PR Newswire)
Nov-03-21 04:05PM	Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 (PR Newswire)
Oct-13-21 04:05PM	Trevi Therapeutics to Present at 11th World Congress on Itch (WCI) (PR Newswire) -8.39%
Oct-12-21 05:01AM	46 Biggest Movers From Yesterday (Benzinga)
Oct-11-21 07:01AM	15 Stocks Moving in Monday's Pre-Market Session (Benzinga) +25.00%
Oct-07-21 04:05PM	Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference (PR Newswire)
Sep-30-21 06:57PM	Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market (PR Newswire)
Aug-12-21 04:05PM	Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update (PR Newswire)
Aug-09-21 04:05PM	Trevi Therapeutics Announces Additions to the Senior Leadership Team (PR Newswire)
Aug-05-21 04:05PM	Trevi Therapeutics to Report Q2 2021 Financial Results on August 12 (PR Newswire)
Jun-09-21 07:30AM	Trevi Therapeutics to Present at 2021 BIO Digital Conference (PR Newswire)
May-13-21 04:05PM	Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update (PR Newswire) -6.51%
02:30PM	Trevi Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
May-06-21 04:05PM	Trevi Therapeutics to Report Q1 2021 Financial Results on May 13 (PR Newswire)
Apr-07-21 07:30AM	Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-21 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates (GlobeNewswire)
02:30PM	Trevi Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
Mar-18-21 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25 (GlobeNewswire)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Delfini Lisa	Chief Financial Officer	Sep 11	Option Exercise	0.51	2,291	1,171	35,105	Sep 13 04:06 PM
Delfini Lisa	Chief Financial Officer	Sep 11	Sale	2.20	711	1,564	34,394	Sep 13 04:06 PM
Delfini Lisa	Chief Financial Officer	Aug 11	Option Exercise	0.51	2,292	1,171	33,496	Aug 14 04:00 PM
Delfini Lisa	Chief Financial Officer	Aug 11	Sale	2.36	682	1,610	32,814	Aug 14 04:00 PM
Delfini Lisa	Chief Financial Officer	Jul 11	Option Exercise	0.51	2,292	1,171	31,891	Jul 12 04:29 PM
Delfini Lisa	Chief Financial Officer	Jul 11	Sale	2.34	687	1,608	31,204	Jul 12 04:29 PM
Simon Farrell	Chief Commercial Officer	Jun 20	Option Exercise	0.51	6,250	3,194	45,650	Jun 21 04:00 PM
Delfini Lisa	Chief Financial Officer	Jun 12	Option Exercise	0.51	2,291	1,171	30,209	Jun 14 04:28 PM
Delfini Lisa	Chief Financial Officer	Jun 12	Sale	2.64	610	1,610	29,599	Jun 14 04:28 PM
Delfini Lisa	Chief Financial Officer	May 11	Option Exercise	0.51	2,291	1,171	28,480	May 15 04:00 PM
Delfini Lisa	Chief Financial Officer	May 11	Sale	2.89	562	1,624	27,918	May 15 04:00 PM
Delfini Lisa	Chief Financial Officer	Apr 11	Option Exercise	0.51	2,292	1,171	27,029	Apr 12 05:02 PM
Delfini Lisa	Chief Financial Officer	Apr 11	Sale	1.84	840	1,545	26,189	Apr 12 05:02 PM
Delfini Lisa	Chief Financial Officer	Mar 13	Option Exercise	0.51	2,291	1,171	25,629	Mar 15 04:00 PM
Delfini Lisa	Chief Financial Officer	Mar 13	Sale	1.75	892	1,564	24,737	Mar 15 04:00 PM
Simon Farrell	Chief Commercial Officer	Mar 07	Option Exercise	0.51	18,750	9,581	39,400	Mar 08 04:00 PM
Delfini Lisa	Chief Financial Officer	Feb 13	Option Exercise	0.51	27,500	14,052	31,812	Feb 15 04:01 PM
Delfini Lisa	Chief Financial Officer	Feb 13	Sale	2.45	8,474	20,761	23,338	Feb 15 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRVI | Trevi Therapeutics, Inc.

Upgrade your FINVIZ experience